TBC1D22A-AS1

Across TCGA pan-cancer cohorts, TBC1D22A-AS1 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TBC1D22A-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where TBC1D22A-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TBC1D22A-AS1 is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

STAD, THCA, and LUAD are the cancer types where TBC1D22A-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TBC1D22A-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	All	+0.183	.014	2	view →
THCA	All	All	−0.056	.009	2	view →
LUAD	Male	III,IV	−0.140	.010	1	view →
LIHC	All	All	+0.034	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TBC1D22A-AS1–STAD

Open the STAD breakdown →